



Akebia Therapeutics  
Investor Relations Department  
245 First Street  
Suite 1100  
Cambridge, MA 02142  
United States


Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: AKBA**

Last Trade:	15.69
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	-0.61 <span style="color: red;">↓</span> (3.742%)
Day Range	15.63 - 16.44
52-Week Range	7.16 - 16.54
Volume	327,402

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jun 20, 2017*

[Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017](#)

*Jun 5, 2017*

[Akebia Prevails in Two Additional European Patent Disputes](#)

*May 25, 2017*

[Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer](#)

*May 24, 2017*

[Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents](#)

*May 15, 2017*

[Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval](#)

### Financials [\[ View all \]](#)

*Mar 6, 2017*

[Annual Report \(10-K\)](#)

*May 1, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 9, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)